CLSA Co-Hosting Multi-State Life Sciences Association Congressional Briefing, June 24, 2015 (D.C.)

May 21, 2015


Nearly three years after the implementation of the most recent FDA user fee bill, the FDA Safety and Innovation Act (FDASIA), the next round of user fee negotiations are expected to get underway in the summer of 2015. CLSA is actively working to ensure that California delegation members and staff – especially those who were not engaged in the 2012 reauthorization cycle – are briefed on the importance of FDA user fees to biomedical innovation.

CLSA is working with nearly a dozen state and regional life sciences associations to convene a multi-state congressional briefing on June 24, 2015 in Washington D.C. This briefing will feature representatives from FDA, partner national life sciences associations including AdvaMed, BIO, MDMA and PhRMA, and patient advocates, all highlighting the critical role that FDA’s user fee programs play in supporting the development and evaluation of new treatments and technologies.

Should you have any questions, please contact Jenny Carey, CLSA’s Director of Federal Government Relations & Alliance Development ( or 202-974-6323) or Meghan Drenan, CLSA’s Associate Director of Federal Government Relations ( or 202-974-6322).